Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Amortization of Deferred Charges (2016 - 2023)

Protalix BioTherapeutics has reported Amortization of Deferred Charges over the past 11 years, most recently at $59000.0 for Q4 2023.

  • Quarterly results put Amortization of Deferred Charges at $59000.0 for Q4 2023, down 22.37% from a year ago — trailing twelve months through Dec 2023 was $267000.0 (down 11.0% YoY), and the annual figure for FY2023 was $267000.0, down 11.0%.
  • Amortization of Deferred Charges for Q4 2023 was $59000.0 at Protalix BioTherapeutics, down from $60000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for PLX hit a ceiling of $983000.0 in Q2 2021 and a floor of $59000.0 in Q4 2023.
  • Median Amortization of Deferred Charges over the past 5 years was $672500.0 (2019), compared with a mean of $485050.0.
  • Biggest five-year swings in Amortization of Deferred Charges: grew 16.48% in 2020 and later tumbled 92.78% in 2022.
  • Protalix BioTherapeutics' Amortization of Deferred Charges stood at $794000.0 in 2019, then grew by 16.12% to $922000.0 in 2020, then plummeted by 88.72% to $104000.0 in 2021, then fell by 26.92% to $76000.0 in 2022, then fell by 22.37% to $59000.0 in 2023.
  • The last three reported values for Amortization of Deferred Charges were $59000.0 (Q4 2023), $60000.0 (Q3 2023), and $68000.0 (Q2 2023) per Business Quant data.